4.7 Article

Analysis of the actions of the novel dopamine receptor-directed compounds (S)-OSU6162 and ACR16 at the D2 dopamine receptor

Journal

BRITISH JOURNAL OF PHARMACOLOGY
Volume 161, Issue 6, Pages 1343-1350

Publisher

WILEY
DOI: 10.1111/j.1476-5381.2010.01010.x

Keywords

OSU6162; ACR16; dopamine stabilizers; D-2 dopamine receptor; radioligand binding; stimulation of [35S]GTP gamma S binding; allosteric effects

Funding

  1. BBSRC

Ask authors/readers for more resources

BACKGROUND AND PURPOSE The two phenylpiperidines, OSU6162 and ACR16, have been proposed as novel drugs for the treatment of brain disorders, including schizophrenia and Huntington's disease, because of their putative dopamine stabilizing effects. Here we evaluated the activities of these compounds in a range of assays for the D-2 dopamine receptor in vitro. EXPERIMENTAL APPROACH The affinities of these compounds for the D-2 dopamine receptor were evaluated in competition with [3H]spiperone and [3H]NPA. Agonist activity of these compounds was evaluated in terms of their ability to stimulate [35S]GTP gamma S binding. KEY RESULTS Both compounds had low affinities for inhibition of [3H]spiperone binding (pK(i) vs. [3H]spiperone, ACR16: < 5, OSU6162: 5.36). Neither compound was able to stimulate [35S]GTP gamma S binding when assayed in the presence of Na+ ions, but if the Na+ ions were removed, both compounds were low-affinity, partial agonists (E-max relative to dopamine: ACR16: 10.2%, OSU6162:54.3%). Schild analysis of the effects of OSU6162 to inhibit dopamine-stimulated [35S]GTP gamma S binding indicated Schild slopes of similar to 0.9, suggesting little deviation from competitive inhibition. OSU6162 was, however, able to accelerate [3H]NPA dissociation from D-2 dopamine receptors, indicating some allosteric effects of this compound. CONCLUSIONS AND IMPLICATIONS The two phenylpiperidines were low-affinity, low-efficacy partial agonists at the D-2 dopamine receptor in vitro, possibly exhibiting some allosteric effects. Comparing their in vitro and in vivo effects, the in vitro affinities were a reasonable guide to potencies in vivo. However, the lack of in vitro-in vivo correlation for agonist efficacy needs to be further addressed. LINKED ARTICLES This article is part of a themed section on Analytical Receptor Pharmacology in Drug Discovery. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2010.161.issue-6.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available